identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1

Ewa A. Jankowska, Gerasimos S. Filippatos, Stephan von Haehling, Jana Papassotiriou, Nils G. Morgenthaler, Mariantonietta Cicoira, Joerg C. Schefold, Piotr Rozentryt, Beata Ponikowska, Wolfram Doehner, Waldemar Banasiak, Oliver Hartmann, Joachim Struck, Andreas Bergmann, Stefan D. Anker, Piotr Ponikowski

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP). Methods: We examined 491 patients with systolic CHF (age: 63±11 years, 91%men, New York Heart Association [NYHA] class [I/ II/III/IV]: 9%/45%/38%/8%, 69% ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. Results: Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p

Original languageEnglish
Article numbere14506
JournalPLoS One
Volume6
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

endothelins
Biomarkers
Endothelin-1
heart failure
biomarkers
Heart Failure
natriuretic peptides
Plasmas
Brain Natriuretic Peptide
Mortality
heart
Stroke Volume
creatinine
Creatinine
chemiluminescence immunoassays
Systolic Heart Failure
Chemiluminescence
Luminescence
Immunoassay
ROC Curve

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Jankowska, E. A., Filippatos, G. S., von Haehling, S., Papassotiriou, J., Morgenthaler, N. G., Cicoira, M., ... Ponikowski, P. (2011). identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One, 6(1), [e14506]. https://doi.org/10.1371/journal.pone.0014506

identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. / Jankowska, Ewa A.; Filippatos, Gerasimos S.; von Haehling, Stephan; Papassotiriou, Jana; Morgenthaler, Nils G.; Cicoira, Mariantonietta; Schefold, Joerg C.; Rozentryt, Piotr; Ponikowska, Beata; Doehner, Wolfram; Banasiak, Waldemar; Hartmann, Oliver; Struck, Joachim; Bergmann, Andreas; Anker, Stefan D.; Ponikowski, Piotr.

In: PLoS One, Vol. 6, No. 1, e14506, 2011.

Research output: Contribution to journalArticle

Jankowska, EA, Filippatos, GS, von Haehling, S, Papassotiriou, J, Morgenthaler, NG, Cicoira, M, Schefold, JC, Rozentryt, P, Ponikowska, B, Doehner, W, Banasiak, W, Hartmann, O, Struck, J, Bergmann, A, Anker, SD & Ponikowski, P 2011, 'identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1', PLoS One, vol. 6, no. 1, e14506. https://doi.org/10.1371/journal.pone.0014506
Jankowska, Ewa A. ; Filippatos, Gerasimos S. ; von Haehling, Stephan ; Papassotiriou, Jana ; Morgenthaler, Nils G. ; Cicoira, Mariantonietta ; Schefold, Joerg C. ; Rozentryt, Piotr ; Ponikowska, Beata ; Doehner, Wolfram ; Banasiak, Waldemar ; Hartmann, Oliver ; Struck, Joachim ; Bergmann, Andreas ; Anker, Stefan D. ; Ponikowski, Piotr. / identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. In: PLoS One. 2011 ; Vol. 6, No. 1.
@article{ed365118f1a243f5a738b3ac7330b53b,
title = "identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1",
abstract = "Objectives: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP). Methods: We examined 491 patients with systolic CHF (age: 63±11 years, 91{\%}men, New York Heart Association [NYHA] class [I/ II/III/IV]: 9{\%}/45{\%}/38{\%}/8{\%}, 69{\%} ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. Results: Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95{\%} confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p",
author = "Jankowska, {Ewa A.} and Filippatos, {Gerasimos S.} and {von Haehling}, Stephan and Jana Papassotiriou and Morgenthaler, {Nils G.} and Mariantonietta Cicoira and Schefold, {Joerg C.} and Piotr Rozentryt and Beata Ponikowska and Wolfram Doehner and Waldemar Banasiak and Oliver Hartmann and Joachim Struck and Andreas Bergmann and Anker, {Stefan D.} and Piotr Ponikowski",
year = "2011",
doi = "10.1371/journal.pone.0014506",
language = "English",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1

AU - Jankowska, Ewa A.

AU - Filippatos, Gerasimos S.

AU - von Haehling, Stephan

AU - Papassotiriou, Jana

AU - Morgenthaler, Nils G.

AU - Cicoira, Mariantonietta

AU - Schefold, Joerg C.

AU - Rozentryt, Piotr

AU - Ponikowska, Beata

AU - Doehner, Wolfram

AU - Banasiak, Waldemar

AU - Hartmann, Oliver

AU - Struck, Joachim

AU - Bergmann, Andreas

AU - Anker, Stefan D.

AU - Ponikowski, Piotr

PY - 2011

Y1 - 2011

N2 - Objectives: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP). Methods: We examined 491 patients with systolic CHF (age: 63±11 years, 91%men, New York Heart Association [NYHA] class [I/ II/III/IV]: 9%/45%/38%/8%, 69% ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. Results: Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p

AB - Objectives: We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP). Methods: We examined 491 patients with systolic CHF (age: 63±11 years, 91%men, New York Heart Association [NYHA] class [I/ II/III/IV]: 9%/45%/38%/8%, 69% ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay. Results: Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% confidence interval [CI] 1.04-1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p

UR - http://www.scopus.com/inward/record.url?scp=79251581599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251581599&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0014506

DO - 10.1371/journal.pone.0014506

M3 - Article

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e14506

ER -